KLK3 and prostate carcinoma: In a cohort study of prostate cancer patients, Nepple et al. [15] found that in more than 16% of the cases, abnormal prostate-specific antigen (PSA) results were identified more than six months prior to documented clinician awareness and the diagnosis of prostate cancer.